Vertex announces investigational new drug (ind) application for vx-522, mrna therapy for people with cystic fibrosis, cleared by fda

Boston--( business wire )--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the u.s. food and drug administration has cleared its investigational new drug (ind) application for vx-522, a messenger ribonucleic acid (mrna) therapy targeted at treating the underlying cause of cystic fibrosis (cf) lung disease for the approximately 5,000 people with cf who cannot benefit from a cystic fibrosis transmembrane conductance regulator (cftr) modulator. vertex plans to initiate a single ascending dose clinical trial for vx-522 in people with cf in the coming weeks.
VRTX Ratings Summary
VRTX Quant Ranking